D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSEAMERICAN:OSTX)

Key Points

• D. Boral Capital reiterated a Buy rating on OS Therapies (OSTX) and set a $20 price target.
• Shares trade around $1.63 with a market cap of $64.4M and the company remains unprofitable (last quarter EPS -$0.41; analysts forecast -$0.52 for the year).
• Multiple institutional investors — including CM Management, Geode Capital, Millennium Management and Two Sigma — have recently increased or initiated positions, indicating rising institutional interest.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $20.00 target price on the stock.

OS Therapies Stock Performance

Shares of NYSEAMERICAN:OSTX opened at $1.63 on Thursday. The business has a 50-day moving average price of $1.44 and a 200 day moving average price of $1.56. The company has a market capitalization of $64.43 million, a price-to-earnings ratio of -1.65 and a beta of -2.98. OS Therapies has a 12-month low of $1.15 and a 12-month high of $2.57.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.41) earnings per share (EPS) for the quarter. As a group, equities research analysts predict that OS Therapies will post -0.52 earnings per share for the current fiscal year.

Institutional Trading of OS Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of the business. CM Management LLC increased its position in shares of OS Therapies by 6.7% during the 3rd quarter. CM Management LLC now owns 400,000 shares of the company's stock worth $784,000 after purchasing an additional 25,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in OS Therapies by 31.1% during the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company's stock valued at $344,000 after acquiring an additional 58,350 shares during the period. Millennium Management LLC purchased a new position in OS Therapies during the 3rd quarter valued at about $183,000. Two Sigma Investments LP purchased a new position in OS Therapies during the 3rd quarter valued at about $169,000. Finally, Virtu Financial LLC boosted its holdings in OS Therapies by 252.0% during the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company's stock valued at $149,000 after acquiring an additional 54,269 shares during the period.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.